Using IL-2 Gene-Modified Immune Cells to Treat Cancer
Author Information
Author(s): Schmidt-Wolf I G H, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft H-G, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D
Primary Institution: Department of Medicine, Division of Hematology/Oncology, Humboldt-Universität zu Berlin
Hypothesis
Can autologous CIK cells transfected with the IL-2 gene improve treatment outcomes in patients with metastatic cancers?
Conclusion
CIK cells transfected with the IL-2 gene can be administered safely and show promise for future cancer therapies.
Supporting Evidence
- CIK cells transfected with IL-2 showed improved proliferation and cytotoxic activity.
- Patients received both transfected and untransfected CIK cells for comparison.
- Significant increases in serum levels of immune markers were observed during treatment.
- One patient with lymphoma achieved a complete response.
Takeaway
Doctors tried using special immune cells that were modified to fight cancer better, and they found it was safe and might help some patients.
Methodology
Patients received infusions of IL-2-transfected CIK cells and untransfected CIK cells for comparison.
Limitations
The study had a small sample size and limited follow-up.
Participant Demographics
Patients with metastatic renal cell carcinoma, colorectal carcinoma, and lymphoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website